Floatz logo

Neoantigen Reactive T Cells

HCC

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolCell therapyPhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

26 Active assets in the HCC cohort.

Asset / SponsorPhaseRating
EOB-DTPA
Charite University, Berlin, Germany
Phase 4BB
CARVEDILOL
Tongji Hospital
Phase 4BB
Hepcortespenlisimut-L
Immunitor LLC
Phase 3B
Tirelizumab
Chen Xiaoping
Phase 4B
ASCRINVACUMAB
Suzhou Kintor Pharmaceutical Inc,
Phase 2B

View all 38 →

Same molecule, other indications

Neoantigen Reactive T Cells is also rated in:

Nicotine DependenceDormant
BB
Indicative ·
70 / 100
View asset →
SchizophreniaDormant
B
Indicative ·
56 / 100
View asset →
Advanced Malignant Solid TumorDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →